The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities - 2009/09/01 - Business Insights

Report title: The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities

from Business Insights
194 page report published Sep 01, 2009

Price $3,835.00 available for immediate download

Report Overview

Table of Contents

Search Inside

About Business Insights

IntroductionRecently, the countries of the Middle East have become increasingly important markets as a result of substantial investment in both the private and public sectors, introduction of mass health insurance and several moves to liberalize national economies. Egypt, Turkey, Saudi Arabia, Israel, Jordan, United Arab Emirates, Lebanon and Kuwait are the major countries of the Middle East with a total population of around 213m. Turkey, one of the key pharmerging markets of the world, is a strong proponent of liberal trade and investment policies. It has an open trading system, especially with countries in the EU, with which it forged a customs union agreement in 1996. Among the Gulf countries, Saudi Arabia is considered as the most attractive healthcare market in the Gulf which is mainly because of its rapidly growing population, enormous economic resources.The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region.Key findings
- The Middle East pharmaceutical market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn in 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn in 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
- General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
- The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.Key features of this report
- The macroeconomic environment in the Middle East countries includes the population profile, disease burden and macroeconomic comparison (involving economic landscape and healthcare spending) for all the major Middle East markets
- Profiles of the healthcare system across the 8 markets (Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon and Kuwait) of the Middle East region
- Overview of key recent events in the Middle East pharmaceutical market that have impacted treatment trends and sales potential across all the Middle East countries
- Forecasts and analysis of the leading products in the Middle East market over the period 2008'14 spread across the major indications and classes of treatmentsUse this report to
- Develop insights for the Middle East pharmaceutical market, pricing & regulation and detailed epidemiological status of the common indications/risk factors across 8 major countries of the Middle East region
- Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Middle East market place
- Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Middle East marketDiscov

Source:

Business Insights

Document ID:

rbhc0241

Industry:

Pharmaceutical

Free Sample:

Click Here to Download

Format:

PDF

Title	Starting Page	Number of Pages
Sections
Table of Contents The Middle Eastern Pharmaceutical Market Outlook to 2014 Executive Summary 12 The macroeconomic environment in the Middle East 12 Healthcare systems in the Middle East 13 Pharmaceutical market analysis of the Middle East 14 Competitive la	0	1
Table of Contents	0	1
The Middle Eastern Pharmaceutical Market Outlook to 2014	0	1
Executive Summary 12	0	1
The macroeconomic environment in the Middle East 12	0	1
Healthcare systems in the Middle East 13	0	1
Pharmaceutical market analysis of the Middle East 14	0	1
Competitive landscape of the Middle Eastern pharmaceutical market 15	0	1
Scope and Methodology 18	0	1
Scope 18	0	1
Methodology 18	0	1
Chapter 1 The macroeconomic environment in the Middle East 20	0	1
Summary 20	0	1
Introduction 21	0	1
Population profile 22	0	1
Disease burden 24	0	1
Macroeconomic comparison of the Middle East 30	0	1
Economic landscape of key Middle Eastern countries 32	0	1
Egypt 32	0	1
Turkey 33	0	1
Saudi Arabia 34	0	1
Israel 35	0	1
Jordan 36	0	1
UAE 36	0	1
Lebanon 38	0	1
Kuwait 38	0	1
Healthcare spending 39	0	1
Chapter 2 Healthcare systems in the Middle East 42	0	1
Summary 42	0	1
Introduction 43	0	1
Profiles of the healthcare systems across Middle Eastern countries 43	0	1
Egypt 43	0	1
Healthcare system 43	0	1
Intellectual property rights 44	0	1
Pricing and reimbursement 45	0	1
Key recent events 46	0	1
Turkey 47	0	1
Healthcare system 47	0	1
Intellectual property rights 49	0	1
Pricing and reimbursement 50	0	1
Key recent events 52	0	1
Saudi Arabia 53	0	1
Healthcare system 53	0	1
Intellectual property rights 54	0	1
Pricing and reimbursement 55	0	1
Key recent events 57	0	1
Israel 58	0	1
Healthcare system 58	0	1
Intellectual property rights 58	0	1
Pricing and reimbursement 59	0	1
Key recent events 61	0	1
Jordan 62	0	1
Healthcare system 62	0	1
Intellectual property rights 63	0	1
Pricing and reimbursement 63	0	1
Key recent events 64	0	1
UAE 65	0	1
Healthcare system 65	0	1
Intellectual property rights 66	0	1
Pricing and reimbursement 67	0	1
Key recent events 68	0	1
Lebanon 68	0	1
Healthcare system 68	0	1
Intellectual property rights 69	0	1
Pricing and reimbursement 70	0	1
Key recent events 71	0	1
Kuwait 71	0	1
Healthcare system 71	0	1
Intellectual property rights 72	0	1
Pricing and reimbursement 72	0	1
Key recent events 73	0	1
Chapter 3 Pharmaceutical Market analysis in the Middle East 76	0	1
Summary 76	0	1
Introduction 77	0	1
Pharmaceutical market overview 77	0	1
Therapy area analysis 80	0	1
Therapy area sales forecast 81	0	1
Therapy area analysis by country 82	0	1
Egypt 82	0	1
Turkey 85	0	1
Saudi Arabia 88	0	1
Israel 90	0	1
Jordan 93	0	1
UAE 94	0	1
Lebanon 97	0	1
Kuwait 100	0	1
Leading brands analysis 103	0	1
Seretide (GSK) 104	0	1
Lipitor (Pfizer) 104	0	1
Augmentin (GSK/MUP) 104	0	1
Glivec (Novartis) 105	0	1
Co-Diovan (Novartis) 105	0	1
Spiriva (Boehringer Ingelheim) 106	0	1
Plavix (Sanofi-Aventis) 106	0	1
Cipralex (Lundbeck) 107	0	1
Lansor (Sanovel) 107	0	1
Symbicort (AstraZeneca) 108	0	1
Leading brands sales forecast 108	0	1
Key brand analysis by country 110	0	1
Egypt 110	0	1
Flumox and Cefotax (Eipico) 110	0	1
Amaryl (Sanofi-Aventis) 111	0	1
Cataflam (Novartis) 111	0	1
Augmentin (MUP) 111	0	1
Turkey 112	0	1
Foradil Combi (Novartis) 113	0	1
Taxotere (Sanofi-Aventis) 113	0	1
Herceptin (Roche) 114	0	1
Saudi Arabia 114	0	1
Augmentin (GSK) 115	0	1
Snafi (Spimaco) 116	0	1
Viagra (Pfizer) 116	0	1
Nexium (AstraZeneca) 116	0	1
Israel 116	0	1
Norditropin (Novo Nordisk) 117	0	1
Seretide (GSK) 118	0	1
Tritace (Sanofi-Aventis) 118	0	1
Jordan 118	0	1
Amoclan (Hikma) 119	0	1
Similac Gain and Similac Advance (Abbott Nutrition) 119	0	1
Cerelac (Nestle) 120	0	1
United Arab Emirates 121	0	1
Cialis (Eli Lilly) 121	0	1
Plavix (Sanofi-Aventis) 122	0	1
Zinnat (GSK) 122	0	1
Lebanon 122	0	1
Pariet (J&J) 123	0	1
Concor (Merck KGaA) 123	0	1
Crestor (AstraZeneca) 124	0	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

Business Insights provides a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors.

Price: $3,835.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.